A kidney transplant recipient with progressive malakoplakia triggered by multidrug-resistant Escherichia coli was successfully treated with a first-in-human engineered bacteriophage cocktail, researchers reported. Bacteriophages — or phages — are viruses that target and consume bacteria. They have shown promise in recent years as a nontraditional alternative to antibiotics for patients with